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OBJECTIVES We compared the safety, tolerance and effectiveness of overdrive high right atrial (RA),
dual-site RA and support (DDI or VDI) pacing (SP) in patients with symptomatic atrial
fibrillation (AF) and bradycardias.
BACKGROUND Optimal pacing methods for AF prevention remain unclear.
METHODS Patients (n  118) were randomized to each of three pacing modes in a crossover trial.
RESULTS Mode adherence was superior for dual-site RA (5.8 months) compared with SP (3.3 months;
p  0.001) and high RA pacing (4.7 months; p  0.006). Adverse event-free survival
improved with dual-site RA (p  0.007 vs. SP) and was comparable to high RA (p  0. 75).
AF-free survival trended to improve with dual-site RA (hazard ratio [HR] 0.715, p  0.07
vs. SP) but not high RA (HR  0.71, p  0.19) or when dual-site RA was compared with
high RA (HR  0.835, p  0.175). Time-to-recurrence was longer in dual-site RA (1.77
months) compared with high RA (0.62 months, p  0.09) or SP (0.44 months, p  0.05).
In antiarrhythmic drug-treated patients, dual-site RA reduced recurrence risk compared with
SP (HR  0.638, p  0.011) and high RA (HR  0.669, p  0.06). In patients with 1
AF event/week, dual-site RA improved AF suppression (HR  0.464, p  0.004 vs. SP;
HR  0.623, p  0.006 vs. high RA). Dual-site RA improved AF-free and mode survival
(p  0.03 vs. high RA, p  0.001 vs. SP) and reduced asymptomatic AF (p  0.01 vs. high
RA).
CONCLUSIONS Dual-site RA is safe and better tolerated than high RA and SP. In patients on antiarrhyth-
mics, dual-site RA prolonged and high RA trended to prolong time-to-recurrent AF
compared with SP. Dual-site RA provides superior symptomatic and asymptomatic AF
prevention compared with high RA in patients with symptomatic AF frequency of
1/week. (J Am Coll Cardiol 2002;40:1140–50) © 2002 by the American College of
Cardiology Foundation
Atrial fibrillation (AF) is a highly prevalent arrhythmia and
a recognized risk factor for stroke and excess mortality (1).
Recurrence of AF is common during antiarrhythmic drug
treatment, often progressing to permanent AF (2–4). Atrial
pacing has reduced the incidence of permanent AF in
patients with bradycardias (5,6). Recently dual-site right
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atrial (RA) and biatrial pacing has been used in drug-
refractory AF (7,8). These two novel pacing methods can
reduce global atrial activation time, eliminate conduction
delays encountered by premature atrial beats that initiate AF
and prevent AF initiation with programmed atrial stimula-
tion (9,10). With long-term application in combination
with antiarrhythmic drugs, dual-site RA pacing has been
shown to increase arrhythmia-free intervals and reduce
progression to permanent AF. The optimal pacing method
alone or in combination with antiarrhythmic drug therapy
with respect to AF prevention, patient safety and pacing
mode tolerance in a symptomatic AF population is un-
known. In 1996, we initiated an intermediate-term, pro-
spective randomized crossover single blind trial to study the
safety, tolerance and effectiveness of overdrive high RA and
dual-site RA pacing as compared with support pacing in
patients with symptomatic AF and bradyarrhythmias in
whom permanent cardiac pacing was indicated.
METHODS
Structure of the trial. The Dual-Site Atrial Pacing to
Prevent Atrial Fibrillation (DAPPAF) trial enrolled pa-
tients from 13 clinical sites in North America (Appendix).
The protocol was approved by institutional review commit-
tees, the U.S. Food and Drug Administration and moni-
tored by an independent data safety and monitoring board.
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The trial was supported by a research grant from Medtronic,
Inc. (Minneapolis, MN), and all investigators agreed to
established conflict of interest standards (11). The trial
design and techniques have been reported (12). The primary
objectives of the study were to determine whether the
dual-site RA pacing system and mode is safe, to compare
the time-to-first recurrence of clinically significant symp-
tomatic AF episodes and to compare the quality of life of
patients among the three pacing modes. Patients who were
21 to 80 years of age with two or more symptomatic AF
events in the previous three months with a spontaneous or
drug-induced bradyarrhythmia requiring permanent pacing
were included. Patients with implantable cardioverter-
defibrillators, contraindications to pacemaker implantation
or anticipated life expectancy 18 months were excluded.
Enrolled patients underwent insertion of a dual-chamber
rate-responsive pulse generator with programmable polarity
to allow high RA only and dual-site RA pacing. The
pacemaker is capable of automatic switching between dual
chamber and ventricular pacing and has device memory for
stored electrograms from AF events (8). Pulse generators
were connected to two RA leads that were placed at the
high RA and outside the coronary sinus ostium via a
Y-connector, along with a right ventricular lead. Dual-site
RA pacing was confirmed with typical inverted or biphasic
P waves (8,9). Antiarrhythmic drugs were continued for AF
suppression and stabilized for two weeks after device im-
plantation. Patients were advised to maintain a stable drug
regimen throughout the trial. Each patient was assigned to
the three pacing modes, that is, dual-site RA overdrive, high
RA overdrive or support pacing for six months each in a
randomized sequence for a maximum total follow-up period
of 18 months. Recommended lower rates for overdrive
pacing were 80 beats/min for arrhythmia suppression.
Modes selected for support pacing (randomized by center)
were DDI at 50 beats/min to provide “low” rate atrial pacing
or no atrial pacing using the VDI mode. These rates and
modes were chosen to address clinical practice and previous
clinical studies at the time of study initiation, which had not
included a control arm to conclusively prove benefit of atrial
pacing. They were designed to prevent symptomatic brady-
cardia yet minimize atrial pacing. Patients were crossed over
to the next assigned mode by an investigator if they were
intolerant to a mode (persistent low cardiac output symp-
toms, syncope or near syncope, congestive heart failure,
symptomatic pacemaker syndrome) despite all efforts to
maintain the mode or after two electrocardiographically
documented symptomatic AF recurrences. Diaries were
used to document symptoms. Quality-of-life measurements,
two-dimensional echocardiographic and Doppler examina-
tions were performed at study entry (baseline) and at every
mode change. An AF symptom checklist, a health status
questionnaire and the Ferrans and Powers Cardiac Version
III quality-of-life index were used to assess quality-of-life
(12).
Pacing systems and implantation. Pacemaker pulse gen-
erators and leads used in this study were approved and
market released by the U.S. or Canadian governmental
authorities. The technique for device insertion has been
described (7,12). The protocol recommended a lower pacing
rate of 80 beats/min for overdriven AF suppression. AF
events were logged using programmed “high rate atrial
events” defined as10 beats at 180 beats/min with the time
and date of the first seven episodes. Event counters up to
255 episodes and stored atrial electrograms were used to
validate AF events. AF recurrences required patient symp-
toms and documentation of AF.
Study end points and analysis. The major study end
points were safety, including adherence to pacing mode, the
time-to-first symptomatic AF recurrence and quality-of-life
measures for AF-related symptoms and general health.
Secondary objectives included comparison of all AF epi-
sodes (symptomatic or asymptomatic) between these pacing
modes and comparison of the two support pacing modes
(DDI and VDI). The study design projected a doubling of
time-to-first recurrence with high RA pacing and a further
50% increase with dual-site RA pacing for sample size
calculations with a power level of 80%. The Data Safety
Monitoring Board and an events subcommittee adjudicated
events and monitored patient safety. An intention to treat
analysis was used with Kaplan-Meier actuarial survival
curves being used to present outcome in each pacing mode.
Statistical significance of unpaired and paired data was
performed to allow for censoring as a result of crossover in
each pacing mode. A relative risk assessment using hazard
ratios from an extended Cox model was used for significance
for unpaired data. Patients undergoing early crossover in a
given mode were eliminated from paired analysis. A gener-
alized Wilcoxon sign test was used for paired data compar-
isons between modes. Multiple comparisons for the SF-36
data had their critical p values adjusted for this analysis.
Prospectively determined subgroup analyses included an-
tiarrhythmic drug use, and additional subgroup analyses
were performed on individual baseline variables, including
bradycardia indication, concomitant cardiovascular disease,
AF event history and by center. Clinically relevant compos-
ite end points for efficacy and safety of individual pacing
modes were not predetermined and were selected by the
investigators at study completion before final data analysis.
Subgroup analysis for asymptomatic AF episodes was only
performed in patients with14 days follow-up in each arm,
with either 255 mode switch or high rate events during
both arms or if 255 events in one arm had a comparable
period of observation in the other arm.
Abbreviations and Acronyms
AF  atrial fibrillation
DAPPAF  Dual-Site Atrial Pacing for Prevention of
Atrial Fibrillation
RA  right atrial
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RESULTS
Of the 120 patients enrolled, two patients declined device
insertion. Seventy-three men and 45 women with a mean
age of 66  11 years were randomized. They had recurrent,
symptomatic AF, with paroxysmal AF episodes in 82
patients, persistent AF episodes for 72 h in 30 patients
and with persistent AF of 30 days in duration in 6
patients. Ninety-two patients had cardiovascular disease,
with coronary disease in 36, systemic hypertension in 69,
valvular disease in 21 and cardiomyopathy in 14. Their
mean left atrial diameter was 40  6 mm, RA diameter 42
 9 mm and the left ventricular ejection fraction was 50 
12%. Pacing indications were sinus bradycardia (n  64),
sinus arrest (n  18), drug-induced bradycardia (n  23),
asymptomatic sinus node dysfunction (n  9), carotid sinus
hypersensitivity (n  1) or other conditions (n  11).
Symptomatic AF event frequency at enrollment was 1
event per day in 40 patients, weekly in 44 patients and
monthly or less in 34 patients. Antiarrhythmic therapy
included class 1 drugs in 24 patients, class 3 drugs in 48
patients, beta-blockers in 33 patients, calcium blockers in 15
patients and digoxin in 29 patients.
Pacemaker system insertion and antiarrhythmic drug
selection. The pacing threshold for dual-site RA pacing
was higher than high RA pacing (1.3  0.9 vs. 0.9  0.7 V
at 0.5 ms pulse duration, p  0.05). This was due to the
higher impedance in dual-site RA pacing (833  297 vs.
578  229 ohms, p  0.05). The mean pacing lower rate in
the support arm was 55  13 beats/min with 23  29%
ventricular pacing. In the high RA pacing arm, the mean
lower rate was 79 5 beats/min, similar to the dual-site RA
pacing arm at 79  4 beats/min (p  0.2). The upper rate
during high RA and dual-site RA pacing was also compa-
rable (132 8 vs. 131 7 beats/min, p 0.2). The percent
atrial pacing achieved, determined by both programming
and AF suppression, was lower in high RA (71 31%) than
in dual-site RA pacing (78  27%, p  0.02), whereas
ventricular pacing was comparable (94 10% vs. 91 18%
respectively, p  0.05).
Tolerance and complications of individual pacing mod-
es. Patient tolerance of an individual pacing mode assessed
by time-to-crossover was greater with dual-site RA as
compared with high RA pacing (p  0.006) or support
pacing (p 0.001) (Fig. 1A, Table 1). This was also greater
in high RA than support pacing (p  0.001). Thus,
follow-up was longer in the dual-site RA pacing mode as
compared with high RA pacing mode (5.8  2.9 vs. 4.7 
2.3 months, p  0.01). Both overdrive modes achieved a
longer follow-up as compared with the support pacing (3.3
 2.8 months, p  0.001). After randomization, patients
failed to tolerate or complete the selected mode most often
in support pacing (56 patients) as compared with high RA
pacing (31 patients, p  0.05 vs. support) or dual-site RA
pacing (21 patients, p  0.05 vs. support, p  0.05 vs. high
RA pacing). Crossover was due to intolerance of the
bradycardia associated with low demand pacing rate, recur-
rent symptomatic AF, loss of atrioventricular synchrony
with pacemaker syndrome or adverse events (Table 1).
Mode-related adverse events occurred in 21 patients in
support, 11 patients in the high RA pacing and 15 patients
in dual-site RA pacing (p  0.2) (Table 1). Overall adverse
event-free survival was greater in dual-site RA pacing as
compared with support pacing (p  0.007) but not to high
RA pacing (p  0.75) or when high RA pacing was
compared with support pacing (p  0.15). There were four
deaths during the study and no stroke events. Lead dis-
lodgements at the coronary sinus and high RA locations
were infrequent (incidence 1.7%), and their incidence was
comparable between locations (p  0.2)
Eight-eight percent of patients were discharged on anti-
arrhythmic drugs, which were maintained as a stable regi-
men throughout the three pacing modes in 76.4% of the
patients. Changes in antiarrhythmic medications occurred
in 29 patients during the study, and these were comparably
distributed among the modes (p  0.1).
Prevention of recurrent AF. Mean total study follow-up
was 12.1  6.9 months with unequal periods in the
treatment arms as a result of crossovers, study end points or
adverse events. This resulted in a decreased AF recurrence
rate (38.5% in the support mode and 33.7% in the high RA
pacing mode) and significant reduction in paired data
samples for analysis as indicated the figures. Relative risk
(hazard ratio) analyses using the Cox model permitted
inclusion of overall study data. Despite reduced event rates,
in the entire study population the time-to-first symptomatic
recurrence of AF trended to be longer in the dual-site RA
pacing mode than the support mode (Cox proportional
hazards survival ratio 0.715, paired Wilcoxon p 0.07, Fig.
1B). This was significantly longer in the subgroup treated
with class 1 or 3 antiarrhythmic drugs (Cox proportional
hazards survival ratio 0.646, paired Wilcoxon p  0.011)
(Fig. 2). In contrast, high RA pacing showed no benefit
compared with support pacing, irrespective of the presence
or absence of antiarrhythmic drugs (Fig. 2).
Comparison of dual-site RA and high RA pacing for
freedom from all symptomatic AF events in the entire study
population did not show significant benefit by paired
analysis but did demonstrate a modest relative risk reduction
of 16.5%, although this did not achieve significance (Cox
proportional hazards survival ratio 0.835, paired Wilcoxon
p  0.175). In drug-treated patients receiving class 1 or 3
antiarrhythmic drugs who comprised 82% of the study
population, dual-site RA pacing did prolong time-to-first
AF recurrence, with a risk reduction of 33% now approach-
ing significance as compared with high RA pacing (Cox
proportional hazards survival ratio 0.669, paired Wilcoxon
p  0.06). There was no improvement in the absence of
drug therapy (Fig. 2). In patients who developed recurrent
AF, the median time-to-recurrence was longest in dual-site
RA pacing (1.77 months) compared with high RA pacing
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(0.62 months, p  0.09) or support pacing (0.44 months,
p  0.05 vs. dual RA, p  0.7 vs. high RA).
In patients on class 1 or 3 antiarrhythmic drugs with a
baseline symptomatic AF event rate 1 per week (78
patients, 66% of the study population), there was a signif-
icantly longer AF-free survival with dual-site RA pacing as
compared with high RA pacing (Cox proportional hazards
survival ratio 0.46, paired Wilcoxon p  0.006,) or support
pacing (Cox proportional hazards survival ratio 0.623,
paired Wilcoxon p  0.004) (Fig. 3). There was no benefit
of high RA pacing as compared with support pacing in this
subgroup. In patients reporting daily AF, dual-site RA
pacing displayed no benefit compared with support or high
RA pacing. Using data only from the first randomized
treatment arm showed similar trends, but statistical power
was lower.
Quality-of-life and AF symptoms. AF symptom scores
were significantly lower in the high RA pacing mode (p 
0.001) and trended to be lower in dual-site RA (p  0.09)
compared with the support mode, but no differences existed
between dual-site RA and high RA pacing (Fig. 4).
Quality-of-life measurements for physical health measures
showed improvement in high RA pacing compared with
baseline (40  11 vs. 35  10, p  0.05) whereas mental
health measures showed improvement in all three arms
compared with baseline (support 48 11, high RA 51
9, dual-site RA 50  10 vs. 38  11, p  0.05).
Overall efficacy and tolerance of pacing modes. The
major composite end point used time-to-first AF recurrence
coupled with maintenance in a randomized pacing mode.
Dual-site RA pacing was superior to high RA pacing (Cox
proportional hazards survival ratio 0. 687, paired Wilcoxon
p  0.05) and to support pacing (Cox proportional hazards
survival ratio 0.582, paired Wilcoxon p  0.001). High RA
pacing was also superior to support pacing (Cox propor-
tional hazards survival ratio 0.504, paired Wilcoxon p 
0.001). Both dual-site RA pacing and high RA pacing were
superior to support pacing for time-to-first AF recurrence
coupled with time-to-adverse event (p  0.05).
Effect of overdrive pacing mode on symptomatic and
asymptomatic AF frequency. Patients meeting the sub-
group analysis criteria showed a significant decrease in mode
switch events and detected high-rate atrial events with
dual-site RA pacing compared with high RA pacing. Mode
switch events could be assessed in 23 patients and decreased
from a mean value of 234  262 events (mean 2.6  4.9
events/day, median 1.401 events/day) in high RA pacing to
86  74 events (mean 0.71  0.88 events/day, median
0.351 events/day) in dual-site RA pacing (p  0.01, signed
rank Wilcoxon p  0.0017). High-rate atrial events met
inclusion criteria in 16 patients and decreased from a mean
value of 194  147 events (mean 3.0  3.5 events/day,
median 1.915 events/day) in high RA pacing to 70  92
events (mean 0.6  1.0 events/day, median 0.181 events/
day) in dual-site RA pacing (p  0.01, signed rank
Wilcoxon p  0.0042) (Fig. 5).
DISCUSSION
This study was designed as an intermediate term compari-
son of three different pacing modes in patients with recur-
rent, paroxysmal or persistent AF. The support arm was the
control arm with minimal atrial pacing in a highly symp-
tomatic population. The main findings of the study include:
1. Insertion of an additional atrial lead in dual-site RA
pacing systems has acceptable safety and stability com-
pared with standard DDDR pacing systems.
2. Improved adherence to pacing mode with dual-site RA
pacing compared with both high RA and support pacing
in an AF population.
Table 1. Adverse Events in Randomized Atms
Adverse Event Category Support High RA Dual Site Total
Related to pacing mode
Pacemaker syndrome (symptoms, e.g., dizziness,
dyspnea, angina, and other)
15 9 11 35
Syncope 5 1 1 7
Rate control with AV node ablation 1 1 1 3
Far field R wave over sensing 0 0 2 2
Total mode-related adverse events 21 11 15 47
Unrelated to pacing mode
Implant related
Cellulitis, pocket hematoma/seroma 6
Infection 1
Other implant related 2
Lead dislodgements 5
Non-implant related
Unrelated surgery 3
Other 1
Randomized arm when initially detected 2 9 7 18
Total adverse events 23 20 22 65
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3. Improved outcome with dual-site atrial pacing both for
adherence to the pacing mode and efficacy in the presence
of class 1 or 3 antiarrhythmic drug therapy, especially in
patients with 1 symptomatic AF event per week.
4. Reduction in both symptomatic and asymptomatic AF
events in the patient subgroup whose device datalogs
could be compared in the high RA and dual-site RA
pacing modes.
5. Absence of efficacy with high RA pacing compared with
the support mode possibly related to study power but
improved adherence to the mode.
6. Poor adherence and adverse effect profile with support
pacing in this relatively brief follow-up period.
7. Comparative analysis of AF prevention between pacing
modes is impacted greatly by poor adherence and high
crossover rates in support and overdrive high RA pacing
in this highly symptomatic population.
Safety of dual-site RA pacing and coronary sinus ostium
lead placement. Adverse event rates were comparable for
high and dual RA pacing. Lead dislodgement at for coro-
nary sinus and high RA sites had comparable frequency
with a low incidence sufficient to justify the conclusion that
placement of an additional screw in active fixation lead at
the coronary sinus ostium is safe, has comparable stability to
high RA locations and has an incremental risk of an
additional atrial lead insertion and current drain (Table 1).
Poor tolerance of support pacing was related to either intoler-
ance of pacing rate, recurrent AF or pacemaker syndrome.
Despite theoretical concerns, ischemia or proarrhythmia were
not observed with overdrive pacing, which was well tolerated.
Stroke and mortality were within reported values.
Implementation of long-term atrial pacing. This study
shows the challenge in maintaining patients with AF and
bradyarrhythmias in support and standard high RA pacing
Figure 1. (A) Freedom from crossover within 4.5 months of entering randomized treatment phase for each pacing mode. The percentage of patients
surviving in the mode is tabulated on the Y-axis and the follow-up duration in the mode on the X-axis. Dual right atrial (RA) pacing shows a higher
proportion of patients able to remain in the randomized treatment mode as compared with other modes. Dual, dual-site RA pacing; single, high RA pacing;
support, demand pacing in atrium or ventricle at low support rate. (B) Freedom from all symptomatic atrial fibrillation (AF) in each randomized pacing
mode in the entire study population. Dual RA pacing but not high RA pacing shows a trend to prolongation of time interval to AF recurrence.
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in the DDDR mode. In a population of sick sinus syndrome
patients in the Mode Optimization Study, Lamas et al. (13)
demonstrated a high crossover rate exceeding 30% at one
year with ventricular demand pacing. Over 50% of patients
in support pacing and 30% in high RA pacing could not
maintain the pacing mode beyond four months in our AF
population. Thus, assessment of efficacy of preventive pac-
ing for any significant period is unlikely to be achieved. This
experience also suggests that substantial preventive pacing
cannot be achieved on a long-term basis in these modes.
These data may also require significant adjustment of
sample size and/or duration for paired data analysis with
acceptable power in atrial pacing trials in symptomatic AF
populations. Adherence to dual-site RA pacing, a measure
of adverse events and symptomatic AF recurrences leading
to crossover, was clearly superior to both support and high
RA pacing. Thus, long-term application of this atrial pacing
mode is feasible and should favor its application in this
population.
Efficacy of high RA and support pacing for AF preven-
tion. Previous studies of high RA pacing have noted that
relatively long follow-up periods show lower incidence of
AF as compared with ventricular pacing in patients with
bradycardias without antecedent AF (9,10). However,
proarrhythmia with ventricular pacing cannot be excluded.
We minimized the potential proarrhythmic effect of ven-
tricular pacing by maintaining a low percent pacing in the
support arm. We also improved the detection of AF
recurrences with electrogram confirmation to validate pa-
tient symptoms. Unlike other recent trials in whom AF
recurrences of 10 min in duration were not included, our
analysis includes any symptomatic recurrence (14). In con-
trast to populations with bradycardia, our study suggests
high RA pacing is preferable to support pacing in an AF
population because of better patient tolerance rather than
efficacy. These data suggest that in the population with
recurrent symptomatic AF and bradycardias, the benefits of
high RA pacing cannot be demonstrated in the study period
in question. It is unclear whether a larger sample size or a
longer observation period would show greater efficacy be-
cause a weak trend to benefit was seen in the presence of
antiarrhythmic drugs. However, support pacing is the least
preferred mode in this patient population. This may be due
to high AF recurrence rates and potentially deleterious
Figure 1. Continued.
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hemodynamic effects of right ventricular apical pacing
modes.
Dual-site RA pacing improved efficacy and tolerance.
Dual-site RA pacing showed incremental benefits with
respect to AF prevention derived almost exclusively in the
large (82%) subgroup receiving antiarrhythmic drug ther-
apy. Furthermore improved patient tolerance led to the least
attrition in patient compliance with the pacing mode. This
supports the use of this pacing mode for long-term efforts at
drug-refractory AF prevention with pacing techniques.
Dual-site RA pacing reduced the incidence of recurrent
symptomatic AF in specific AF population subgroups as
well as prolonged time-to-recurrence in patients who expe-
rienced recurrent AF during the study period in comparison
to the other modes, specifically including high RA pacing.
Reduced AF recurrence rates were observed in class 1 or 3
drug-treated individuals and were particularly significant in
patients with frequent but not daily AF (7,15). These
comprised the majority of the sample in this study. Benefits
with respect to symptomatic and asymptomatic AF were
also documented by device datalogs in this mode compared
with high RA pacing. These data are best judged for their
significance in the light of the reduced AF event incidence
in the comparison arms resulting from the reduced
follow-up period as a result of high crossover rates in these
arms. These efficacy benefits coupled with the observation
that the dual-site RA pacing mode may have the highest
likelihood of long-term compliance make it preferable to
the other pacing modes.
Clinical relevance of the dual-site RA pacing techni-
que. The clinical relevance of this incremental efficacy in
AF prevention with dual-site RA pacing can be best judged
in comparison to similar trials with antiarrhythmic drugs
and lack of benefit with respect to AF prevention in the
high RA pacing arm. The drug-treated dual-site RA pacing
group had freedom from AF recurrence was 80%, 72% and
72% at two, four and six months of follow-up, often in
drug-refractory patients. In previous reports during flecain-
ide, propafenone or sotalol therapy, freedom from symp-
tomatic AF at six months was 30% to 60%, 45% to 60% and
40% respectively (6,7,14,16). For amiodarone, this value is
estimated at 75% after censoring early recurrences (14).
Thus, dual-site RA pacing provides clinically relevant level of
incremental efficacy for AF suppression in this population.
Figure 2. Freedom from all symptomatic atrial fibrillation (AF) in each randomized pacing mode in study population receiving concomitant class 1 or 3
antiarrhythmic drugs (AAD on the left) or without concomitant drug therapy (AAD on the right). Dual right atrial (RA) pacing but not high RA pacing
shows prolongation of time interval to AF recurrence as compared with support pacing and a trend to prolongation as compared with high RA pacing in
drug-treated patients. There is no difference in outcome in patients on any randomized pacing mode without concomitant drug therapy. AAD antiarrhythmic
drug.
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In comparison with standard high RA pacing, benefits of
dual-site RA pacing with respect to AF prevention become
apparent, even in the relatively short observation period of
this study, in patients reporting frequent (weekly or less
events) but not daily AF. This is a large drug-refractory
patient population, which comprised a majority of our study
patients. In these patients, the addition of this pacing
system improved outcome significantly even in the short-
term, with the potential for long-term benefit. In contrast,
this study and other studies have not demonstrated any
benefit of high RA pacing for prevention of symptomatic
AF (4).
AF recurrences during dual RA pacing diminish with
longer-term follow-up (15). Early recurrence(s) of AF
during dual RA pacing do not predict long-term symptom-
atic AF suppression (15). Thus, a long-term therapeutic
strategy with dual RA pacing could require termination of
early AF recurrences, allowing for pacing to progressively
diminish AF recurrence rates and restore rhythm control in
drug-treated patients (15). For best results, the dual-site RA
pacing technique should be applied in patients with brady-
arrhythmias and symptomatic and refractory AF, in whom
antiarrhythmic drug therapy can and is being continued.
Patients with paroxysmal and persistent AF were included
in this study.
Mechanism of efficacy. Efficacy of dual-site RA pacing
may be due to a variety of synergistic antiarrhythmic effects
(15,17). Continuous overdrive atrial pacing can suppress
atrial premature beats, triggering AF and causing atrial
remodeling (17). Lower rates of 80 beats/min can also
eliminate pauses preceding AF onset. Dual-site RA pacing
abbreviates intra-atrial conduction for the paced as well as
for premature atrial beats, preventing AF initiation
(9,10,18). Drugs may increase AF organization with in-
creased vulnerability to electrical termination (19). Resyn-
chronization of atrial regions by dual-site RA pacing dimin-
ishes heterogeneity of refractoriness and in postoperative
AF has reduced recurrence rates (20). Analysis of echocar-
diographic data from this study, which is being reported
separately, shows a decrease in left ventricular ejection
Figure 3. Freedom from all symptomatic atrial fibrillation (AF) in each randomized pacing mode in study population receiving concomitant class 1 or 3
antiarrhythmic drugs with frequent (weekly events to two events in three months) AF at baseline. Dual right atrial (RA) pacing shows prolongation of time
interval to AF recurrence as compared with high RA or support pacing in these patients.
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fraction and left atrial enlargement with high RA pacing in
the DDDR mode, which is completely attenuated by
dual-site RA pacing (21). Dual-site RA pacing also im-
proved left atrial transport.
Potential role of AF event frequency. Our study popula-
tion is reflective of a large segment of the general AF pool,
but it differed from previous studies in enrolling symptom-
atic AF patients (4,5). Our median AF-free interval was
Figure 4. Quality-of-life in the study population at baseline and in each randomized treatment mode for individual measures. Atrial fibrillation symptom
checklist (paired analysis) in each randomized mode shows the benefits of both overdrive pacing modes as compared with support pacing.
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weekly at study entry. These patients are routinely treated
with antiarrhythmic drugs and show incremental benefit
with the addition of dual RA pacing to drug therapy.
However, the role of pacing in patients with daily AF may
be more limited as a result of the high density of triggers, a
very vulnerable substrate and limited opportunity to estab-
lish continuous pacing. Incessant triggers in this group may
not be fully suppressed by pacing and require additional
interventions. Substrate remodeling because of rapid atrial
rates in AF may make it very vulnerable to AF even with a
few residual triggers. Our end point may also be insensitive
to reductions in AF frequency, burden or progression to
permanent AF in this group. Alternative approaches, such
as ablation, may be used to reduce AF event rate before
pacing.
This study supports the concept of incremental therapy of
the AF patient with hybrid drug and pacemaker therapy in
our study population. A paradigm shift in the treatment of
drug refractory AF in patients with bradycardias using
combined pharmacologic and dual-site RA pacing will
require demonstration of long-term efficacy in AF preven-
tion and applicability of this technique.
Study limitations. This study, as in previous studies in
patients with highly symptomatic tachyarrhythmias, did not
randomize antiarrhythmic drug usage or sequences. Al-
though participants were blinded to the randomized mode,
it is difficult to blind investigators in pacing trials because
electrocardiographic recordings identify the pacing mode.
Crossovers in the support arm reduced event rates and
power, suggesting end points based on multiple symptom-
atic AF recurrences are unlikely to obtain compliance. Thus,
other clinically relevant end points such as our composite
end points, hospitalization and cardioversion may be im-
portant in AF populations. Finally, three paired unadjusted
comparisons were performed between treatment arms for
time-to-symptomatic AF recurrence, and the type 1 error
associated with this hypothesis could be inflated.
Conclusions. We conclude that in patients with bradycar-
dias and AF on antiarrhythmic drugs, dual-site RA pacing
prolonged and high RA pacing trended to prolong time-to-
recurrent AF compared with support pacing. In patients
with weekly or less frequent symptomatic AF recurrences on
antiarrhythmic drug therapy, overdrive dual-site RA pacing
provides more effective prevention of recurrent AF and
improves tolerance for pacemaker therapy with comparable
safety. Larger studies of the two overdrive pacing methods
in combination with drugs and with cost comparisons are
needed. This trial supports longer-term evaluation of over-
drive dual-site RA pacing in other drug-treated AF popu-
lations. It does not support the use of atrial pacing as
monotherapy in this symptomatic AF population.
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APPENDIX
For a complete list of Investigators and Participating Insti-
tutions, please see the September 18 issue of JACC at
www.cardiosource.com/jacc.html.
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